For investors seeking a single-ticket entry into the convergence of artificial intelligence and pharmaceutical innovation, a focused exchange-traded fund offers the most direct pathway.

The Healthcare ETF via Stock Connect (ticker: 159137) stands out as the top-tier choice, featuring the highest concentration of AI-powered drug developers available on the market today.

Specifically, its benchmark index boasts an "AI pharmaceutical content" ratio of 69.5%, the leading figure across all comparable funds. With the MACD indicator flashing a golden cross signal, selected holdings within this portfolio are demonstrating robust upward momentum.